108 results
Keyword Torisel Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Imbruvica (updated)
Ibrutinib, Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014, Revision: 30, Authorised, Last updated: 24/05/2023 -
List item
Human medicine European public assessment report (EPAR): Tygacil
Tigecycline, Bacterial Infections; Skin Diseases, Bacterial; Soft Tissue Infections
Date of authorisation: 24/04/2006, Revision: 34, Authorised, Last updated: 11/10/2022medicines: Conbriza, PecFent and Torisel.3 Why were these medicines … -
List item
Human medicine European public assessment report (EPAR): Carmustine Obvius
carmustine, Hodgkin Disease; Lymphoma, Non-Hodgkin
Date of authorisation: 18/07/2018,
, Revision: 7, Authorised, Last updated: 20/09/2022
-
List item
Human medicine European public assessment report (EPAR): Ribavirin Teva
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 31/03/2009,, Revision: 15, Withdrawn, Last updated: 09/07/2021
medicines: Conbriza, PecFent and Torisel.3 Why were these medicines … -
List item
Human medicine European public assessment report (EPAR): Velcade
bortezomib, Multiple Myeloma
Date of authorisation: 26/04/2004, Revision: 45, Authorised, Last updated: 04/06/2021Cayston, Luminity, Mepact, Torisel and Vibativ)2, initiated … Soliris, Cayston, Mepact, Torisel and Angiox, for which alternative … Velcade, Ecalta, Soliris, Torisel and Cayston should continue … -
List item
Human medicine European public assessment report (EPAR): Fotivda
tivozanib, Carcinoma, Renal Cell
Date of authorisation: 24/08/2017,
, Revision: 8, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Vibativ
telavancin, Pneumonia, Bacterial; Cross Infection
Date of authorisation: 02/09/2011,, Revision: 10, Withdrawn, Last updated: 16/05/2018
Cayston, Luminity, Mepact, Torisel and Vibativ)2, initiated … Soliris, Cayston, Mepact, Torisel and Angiox, for which alternative … Velcade, Ecalta, Soliris, Torisel and Cayston should continue … -
List item
Human medicine European public assessment report (EPAR): Bortezomib Hospira
bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016,, Revision: 12, Authorised, Last updated: 01/03/2022
-
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib (s)-malate, Carcinoma, Renal Cell; Carcinomas, Hepatocellular
Date of authorisation: 09/09/2016,
, Revision: 16, Authorised, Last updated: 05/04/2023
-
List item
Human medicine European public assessment report (EPAR): Angiox
Bivalirudin, Acute Coronary Syndrome
Date of authorisation: 20/09/2004, Revision: 22, Withdrawn, Last updated: 14/09/2018Cayston, Luminity, Mepact, Torisel and Vibativ)2, initiated … Soliris, Cayston, Mepact, Torisel and Angiox, for which alternative … Velcade, Ecalta, Soliris, Torisel and Cayston should continue … -
List item
Human medicine European public assessment report (EPAR): Ribavirin Teva Pharma B.V.
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 01/07/2009,, Revision: 14, Withdrawn, Last updated: 09/07/2021
medicines: Conbriza, PecFent and Torisel.3 Why were these medicines … -
List item
Human medicine European public assessment report (EPAR): Pixuvri
pixantrone dimaleate, Lymphoma, Non-Hodgkin
Date of authorisation: 10/05/2012, Revision: 23, Authorised, Last updated: 07/12/2021 -
List item
Human medicine European public assessment report (EPAR): Vistide
cidofovir, Cytomegalovirus Retinitis
Date of authorisation: 23/04/1997, Revision: 21, Withdrawn, Last updated: 19/01/2015Cayston, Luminity, Mepact, Torisel and Vibativ)2, initiated … Soliris, Cayston, Mepact, Torisel and Angiox, for which alternative … Velcade, Ecalta, Soliris, Torisel and Cayston should continue … -
List item
Human medicine European public assessment report (EPAR): Bortezomib Sun
bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016,, Revision: 12, Authorised, Last updated: 09/09/2021
-
List item
Human medicine European public assessment report (EPAR): Tecartus
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel), Lymphoma, Mantle-Cell
Date of authorisation: 14/12/2020,, 
, 
, Revision: 4, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Afinitor
everolimus, Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms
Date of authorisation: 02/08/2009, Revision: 30, Authorised, Last updated: 27/06/2022 -
List item
Human medicine European public assessment report (EPAR): Revlimid
lenalidomide, Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes
Date of authorisation: 14/06/2007,, Revision: 49, Authorised, Last updated: 02/03/2023
-
List item
Human medicine European public assessment report (EPAR): Inlyta
axitinib, Carcinoma, Renal Cell
Date of authorisation: 03/09/2012, Revision: 14, Authorised, Last updated: 28/09/2021 -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Mesothelioma; Colorectal Neoplasms
Date of authorisation: 19/06/2015, Revision: 52, Authorised, Last updated: 28/03/2023 -
List item
Withdrawn application: Oncophage
date of withdrawal: 23/11/2009, Initial authorisation, Last updated: 21/12/2009 -
List item
Withdrawn application: Sutent
sunitinib, date of withdrawal: 26/06/2018, Post-authorisation, Last updated: 17/08/2018 -
List item
Withdrawn application: Jenzyl
date of withdrawal: 27/11/2012, Initial authorisation, Last updated: 18/02/2013 -
List item
Referral: Medicines studied at Cetero Research facility
fenofibrate, cilazapril, leflunomide, associated names: Cilazapril Teva, Fenofibrato Pensa, Fenofibrato Ranbaxy, Leflunomide Actavis, Leflunomide Apotex, Article 31 referrals
Status: European Commission final decision, opinion/position date: 13/12/2012, EC decision date: 20/02/2013, Last updated: 12/03/2013medicines: Conbriza, PecFent and Torisel.3 Why were these medicines … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/03/2022 to 10/03/2022, Last updated: 22/11/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 November-2 December 2021
European Medicines Agency, Amsterdam, the Netherlands, from 29/11/2021 to 02/12/2021, Last updated: 04/10/2022